FERRITIN is the major iron storage protein in tissues and most of the studies reported since its isolation 40 years ago have related to iron metabolism (Harrison et al., 1974) . More recently, small amounts have been detected in plasma, and in otherwise healthy subjects the concentration of the circulating protein is related to the amount of reticuloendothelial (RE) storage iron in the body . Elevated levels have been reported in leukaemia and Hodgkin's disease (Jones et al., 1973) and, in the case of acute leukaemia, this is associated with increased synthesis and high concentrations in the malignant cells White et al., 1974) . The analysis of normal tissue ferritin by isoelectric focusing has revealed considerable heterogeneity (Drysdale, 1974; Powell et al., 1975) . Alpert, Coston and Drysdale (1973) found human hepatoma tissue to contain an acidic ferritin also present in early foetal liver but not in mature liver. Marcus and Zinberg (1974) showed that ferritin isolated from breast and pancreatic tumour tissue contained acidic isoferritins not found in adult liver, while Drysdale and Singer (1974) demonstrated acidic isoferritins in HeLa cells and in placenta. Both groups of workers suggested the term " carcinofetal " isofoerritin and discussed the possibility of developing serological tests for cancer based on the characteristics of this protein.
The suggestion by Marcus and Zinberg (1974) that breast cancer tissue might produce its own characteristic ferritin, together with their initial report (Marcus and Zinberg, 1975a) of increased serum ferritin concentrations in patients with the disease, stimulated the present study. We have estimated circulating ferritin concentration in 229 women presenting with early breast cancer and compared the data with that from 250 normal women. The relationship between circulating ferritin and recurrence of the tumour has also been examined.
METHODS
Serum samples were collected from 153 apparently healthy, non-anaemic women over the age of 16 years, living in the Cardiff area. Plasma samples were obtained from 97 normal women aged over 18 years living in Guernsey and from 229 women presenting for the first time with untreated breast cancer (Stages I and II) . All samples were coded and ferritin estimations were carried out by the method of Jones and Worwood (1975) . Only when the ferritin levels had been measured was the code broken.
The patients with breast cancer were followed for up to 5 years from the time of presentation and the interval to recurrence was noted. The results of initial serum ferritin estimations were evaluated by standard statistical methods (Siegel, 1956) and the relationship between initial ferritin concentration and recurrence of the cancer was analysed using both the method of Watson (1967) and the log rank test (Peto, 1972) .
RESULTS
There was no significant difference, either in mean values or in distribution, between the normal samples collected in Cardiff and Guernsey. These groups were therefore amalgamated. The total of 250 normal adult women had a mean serum ferritin concentration of 56*6±56-9 and other workers (Cook, Lipschitz and Miles, 1974; Halliday, Gera and Powell, 1975; Marcus and Zinberg, 1975b) There are many possible reasons for high concentrations of circulating ferritin. Levels comparable to those found in the present group of patients could be due to increased iron stores, inflammatory disease, liver damage or malignancy though it is tempting to consider it as the expression of a tumour-produced protein.
The only direct evidence for increased ferritin synthesis in human malignant tissue is that of White et al. (1974) in the case of acute myeloblastic leukaemia. Ferritin has been identified in Hodgkin's tumours (Bieber and Bieber, 1973; Eshhar, Order and Katz, 1974) and in breast tumour (Marcus and Zinberg, 1974 ) but this is not altogether surprising, as the capacity to synthesize this protein has been found in every mammalian tissue studied (Harrison et al., 1974) . Jones et al. (1973) pointed out that neoplasia is commonly associated with an abnormality of iron metabolism which manifests itself by a low serum iron concentration, an increase in RE iron and the anaemia of chronic disease (Cartwright and Lee, 1971) . The majority of patients with Hodgkin's disease show this phenomenon and although it is most marked in those with advanced disease it is present in all stages . The abnormality is thought to reflect a secondary metabolic disorder in RE cells which accumulate ferritin. and release iron only ineffectively to the plasma transferrin pool. In patients with rheumatoid arthritis who display a similar phenomenon, high serum ferritin concentrations are associated with a reduction of serum iron and transferrin saturation. Jones et al. (1973) considered the high serum ferritin in Hodgkin's disease to be a reflection of this RE block of iron release and the data of Jacobs et al. ( 1976) support this concept. It seems likely that a similar state exists in patients with breast cancer and other malignant states.
While Drysdale and Singer (1974) and Marcus and Zinberg (1974) have suggested that tumour cells may produce an acidic " carcinofoetal " isoferritin characteristic of the malignant state, this concept appears to be an over-simplification. There is considerable heterogeneity of the isoferritin pattern found in tumours. This has been demonstrated both in induced rat hepatomas (Urushizaki et al., 1973) and in human myeloblastic leukaemia . Marcus and Zinberg (1974) . There are other serum bands corresponding to the usual tissue ferritins and including acid components (pl 5-0-5-1) similar to those found in HeLa cells, breast cancer, placenta and normal cardiac tissue. Marcus and Zinberg (1975b) suggest that, despite the uncertainties regarding the origin and nature of serum ferritin, its estimation may be of empirical value in cancer immunodiagnosis. While there are undoubted immunological differences between the acidic and alkaline isoferritins (Marcus and Zinberg, 1975b; Jacobs, 1976; and Worwood, Jones and Jacobs, 1976) there is not yet any evidence of a difference between normal and malignant isoferritins which could form the basis of a specific assay.
The present evidence suggests that, while patients with early breast cancer have serum ferritin concentrations somewhat higher than normal, this could result from the non-specific effect of malignancy on RE iron metabolism. The degree of increase is not comparable to that in acute leukaemia, where levels 25 times normal are found (Parry, Worwood and Jacobs, 1975) . Whatever the mechanism of high circulating ferritin levels in cancer patients, the data point to a difference in tumour recurrence rate in the high ferritin group. Tormey et al (1975) 
